IL158534A0 - Oligonucletide compositions and their use to induce differentation of cells - Google Patents
Oligonucletide compositions and their use to induce differentation of cellsInfo
- Publication number
- IL158534A0 IL158534A0 IL15853402A IL15853402A IL158534A0 IL 158534 A0 IL158534 A0 IL 158534A0 IL 15853402 A IL15853402 A IL 15853402A IL 15853402 A IL15853402 A IL 15853402A IL 158534 A0 IL158534 A0 IL 158534A0
- Authority
- IL
- Israel
- Prior art keywords
- cells
- compositions
- seq
- differentiation
- induce
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000024245 cell differentiation Effects 0.000 abstract 2
- 230000004069 differentiation Effects 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000019838 Blood disease Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 206010033661 Pancytopenia Diseases 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 208000034737 hemoglobinopathy Diseases 0.000 abstract 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000002364 leukopenia Diseases 0.000 abstract 1
- 231100001022 leukopenia Toxicity 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 206010043554 thrombocytopenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28615801P | 2001-04-24 | 2001-04-24 | |
| US10/127,645 US7087586B2 (en) | 2001-04-24 | 2002-04-22 | Oligonucleotide compositions and their use to induce differentiation of cells |
| PCT/CA2002/000573 WO2002085340A2 (en) | 2001-04-24 | 2002-04-23 | Oligonucleotide compositions and their use to induce differentiation of cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158534A0 true IL158534A0 (en) | 2004-05-12 |
Family
ID=26825829
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15853402A IL158534A0 (en) | 2001-04-24 | 2002-04-23 | Oligonucletide compositions and their use to induce differentation of cells |
| IL158534A IL158534A (en) | 2001-04-24 | 2003-10-21 | Oligonucleotide compositions and their use to induce cell differentiation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL158534A IL158534A (en) | 2001-04-24 | 2003-10-21 | Oligonucleotide compositions and their use to induce cell differentiation |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7087586B2 (de) |
| EP (1) | EP1381375B1 (de) |
| JP (1) | JP4460220B2 (de) |
| KR (1) | KR100913860B1 (de) |
| AT (1) | ATE489467T1 (de) |
| AU (1) | AU2002252891B2 (de) |
| CA (1) | CA2445071A1 (de) |
| DE (1) | DE60238393D1 (de) |
| IL (2) | IL158534A0 (de) |
| MX (1) | MXPA03009761A (de) |
| NZ (1) | NZ529160A (de) |
| WO (1) | WO2002085340A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1432450E (pt) * | 2001-10-03 | 2006-05-31 | Bioniche Life Sciences Inc | Trietilenoglicol-colesteril-oligonucleotidos terapeuticamente uteis |
| MXPA04010415A (es) * | 2002-04-22 | 2005-02-17 | Bioniche Life Sciences Inc | Composiciones oligonucleotdias y su uso para la modulacion de respuestas inmunes. |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| EP1924279A2 (de) * | 2005-09-07 | 2008-05-28 | The Secretary of State for Defence | Adjuvans-vakzine |
| EP2278979A4 (de) * | 2008-05-21 | 2012-09-26 | Us Gov Health & Human Serv | Verfahren zur behandlung von pneumokoniose mit oligodesoxynukleotiden |
| US8053422B2 (en) | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
| GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
| US5866332A (en) * | 1994-02-02 | 1999-02-02 | Incyte Pharmaceuticals, Inc. | Human myeloid terminal differentiation response gene |
| US5994320A (en) * | 1995-02-06 | 1999-11-30 | Regents Of The University Of Minnesota | Antisense oligonucleotides and methods for treating central nervous system tumors |
| US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
| CA2328406A1 (en) * | 1998-05-14 | 1999-11-18 | Hermann Wagner | Methods for regulating hematopoiesis using cpg-oligonucleotides |
| US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
| MXPA02005842A (es) * | 1999-12-13 | 2003-10-14 | Bioniche Life Sciences Inc | Oligonucleotidos sinteticos terapeuticamente utiles. |
| NZ520312A (en) | 1999-12-28 | 2003-08-29 | Bioniche Life Sciences Inc | Hyaluronic acid in the treatment of cancer |
| MXPA03001812A (es) * | 2000-08-29 | 2004-05-21 | Bioniche Life Sciences Inc | Modulacion de la expresion del sindrome de alcohol fetal y del ligando del sindrome de alcohol fetal.. |
| AU2002330663B2 (en) * | 2001-08-17 | 2007-09-20 | Bioniche Life Sciences, Inc. | Oligonucleotide compositions and their use to induce apoptosis |
-
2002
- 2002-04-22 US US10/127,645 patent/US7087586B2/en not_active Expired - Fee Related
- 2002-04-23 CA CA002445071A patent/CA2445071A1/en not_active Abandoned
- 2002-04-23 NZ NZ529160A patent/NZ529160A/en not_active IP Right Cessation
- 2002-04-23 DE DE60238393T patent/DE60238393D1/de not_active Expired - Lifetime
- 2002-04-23 EP EP02721915A patent/EP1381375B1/de not_active Expired - Lifetime
- 2002-04-23 MX MXPA03009761A patent/MXPA03009761A/es active IP Right Grant
- 2002-04-23 WO PCT/CA2002/000573 patent/WO2002085340A2/en not_active Ceased
- 2002-04-23 IL IL15853402A patent/IL158534A0/xx unknown
- 2002-04-23 AT AT02721915T patent/ATE489467T1/de not_active IP Right Cessation
- 2002-04-23 AU AU2002252891A patent/AU2002252891B2/en not_active Ceased
- 2002-04-23 JP JP2002582914A patent/JP4460220B2/ja not_active Expired - Fee Related
- 2002-04-23 KR KR1020037013799A patent/KR100913860B1/ko not_active Expired - Fee Related
-
2003
- 2003-10-21 IL IL158534A patent/IL158534A/en not_active IP Right Cessation
-
2006
- 2006-06-08 US US11/449,152 patent/US20070010472A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4460220B2 (ja) | 2010-05-12 |
| DE60238393D1 (de) | 2011-01-05 |
| US20070010472A1 (en) | 2007-01-11 |
| KR20040047749A (ko) | 2004-06-05 |
| IL158534A (en) | 2010-06-16 |
| WO2002085340A3 (en) | 2003-10-30 |
| ATE489467T1 (de) | 2010-12-15 |
| US7087586B2 (en) | 2006-08-08 |
| US20030045493A1 (en) | 2003-03-06 |
| EP1381375A2 (de) | 2004-01-21 |
| WO2002085340A2 (en) | 2002-10-31 |
| EP1381375B1 (de) | 2010-11-24 |
| NZ529160A (en) | 2006-06-30 |
| AU2002252891B2 (en) | 2007-09-20 |
| CA2445071A1 (en) | 2002-10-31 |
| MXPA03009761A (es) | 2004-01-29 |
| KR100913860B1 (ko) | 2009-08-26 |
| JP2004526775A (ja) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kutsch et al. | Homologous structures in the nervous systems of Arthropoda | |
| EP2186525A3 (de) | G-CSF zur Behandlung der Parkinson-Krankheit | |
| CA2250682A1 (en) | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes | |
| ATE300613T1 (de) | Menschliche, für zyklische nukleotide spezifische phosphodiesterase | |
| ES2375058T8 (es) | Axmi-010, un gen de la delta-endotoxina y métodos para su uso. | |
| WO2002102997A3 (en) | Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same | |
| EP1778842B8 (de) | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung | |
| SG127738A1 (en) | Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds | |
| BR9206027A (pt) | Análogo de oligonucleotídio, composto de subunidade de oligonucleotídeo, processo para preparar tal composto, processo para modular a produção ou atividade de uma proteína, e, processo para tratar um organismo tendo uma doença distinta pela produção indesejada de uma proteína | |
| WO2005021585A3 (en) | Axmi-003, a delta-endotoxin gene and methods for its use | |
| EP2130839A3 (de) | AXMI-027, AXMI-036 und AXMI-038, Familie von delta-Endotoxin-Genen und Verfahren zur deren Verwendung | |
| AU9084601A (en) | G-csf analog compositions and methods | |
| WO1999066959A3 (en) | Compositions and methods for delivery of genetic material for altering neuronal growth, regeneration, and survival | |
| IL101600A (en) | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them | |
| WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
| JP2003192699A5 (de) | ||
| RU2013156620A (ru) | Индуцирующий иммунитет агент | |
| MXPA05007181A (es) | Cristales de la hormona de crecimiento humano y metodos para prepararlos. | |
| WO2007031319A8 (en) | Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides | |
| IL158534A0 (en) | Oligonucletide compositions and their use to induce differentation of cells | |
| ATE190352T1 (de) | Dorsalgewebe beeinflussender faktor und zusammensetzungen | |
| CY1106041T1 (el) | Καινοφανης συλλεκτινη | |
| ES2173856T3 (es) | Proceso para la preparacion de vectores geneticos para la expresion del factor de crecimiento nervioso en celulas eucariotas. | |
| PL365473A1 (en) | Polyamine analogues as cytotoxic agents | |
| IL141325A0 (en) | Tan-1057 derivatives |